AQST stock forecast suggests earnings momentum will accelerate in H2 2024, underpinned by manufacturing scale-up and improved gross margins. It's good to see that Aquestive Therapeutics has rewarded shareholders with a total shareholder return of 88% in the last twelve months. Notably the five-year annualised TSR loss of 6% per year compares very unfavourably with the recent share price performance. This makes us a little wary, but the business might have turned around its fortunes. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Aquestive Therapeutics has 3 warning signs (and 1 which doesn't sit too well with us) we think you should know about. NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive... AQST stock forecast is supported by technical chart patterns, where the 50-day MA has crossed above the 200-day MA, indicating a bullish golden cross. Momentum traders may eye this setup for a potential run toward $3.
